SYSTEMATIC REVIEW article
Front. Microbiol.
Sec. Systems Microbiology
Volume 16 - 2025 | doi: 10.3389/fmicb.2025.1549499
Systematic Review of Gut Microbiota Composition, Metabolic Alterations, and the Effects of Treatments on PCOS and Gut Microbiota Across Human and Animal Studies
Provisionally accepted
- 1Department of Experimental Pathology and Immunology, Faculty of Medicine, American University of Beirut, Beirut, Lebanon
- 2Center for Infectious Diseases Research, American University of Beirut Medical Center, Beirut, Beyrouth, Lebanon
- 3WHO Collaborating Center for Reference and Research on Bacterial Pathogens, Beirut, Lebanon
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Polycystic ovary syndrome (PCOS) is an endocrine disorder affecting around 12% of women globally, associated with infertility and various comorbidities. Emerging evidence suggests a crucial role of gut microbiota in PCOS pathophysiology. This systematic review analyzes human and animal studies comparing gut microbiota composition, gut-derived metabolites, and treatment interventions in PCOS patients versus healthy controls. A comprehensive literature search was conducted using PubMed, Scopus, and Web of Science. Our analysis revealed decreased alpha diversity in PCOS patients, with more pronounced beta diversity changes in animal models. Specific bacterial taxa, such as Bacteroides vulgatus, Escherichia-Shigella, and Lactobacillus, were implicated in PCOS pathogenesis. Discrepancies between human and animal studies highlight the need for humanized mouse models. Interventions like probiotics and fecal microbiota transplantation (FMT) showed varying efficacy, with FMT emerging as a promising but invasive option. Alterations in gut-derived metabolites, including short-chain fatty acids and bile acids, underscore the complex interplay between PCOS and metabolic pathways. Further research with standardized methods and larger sample sizes is needed to elucidate the microbiome’s role in PCOS and its potential as a therapeutic target.
Keywords: Polycystic Ovary Syndrome, Gastrointestinal microbiome, Endocrine System Diseases, fecal microbiota transplantation, Metagenomics, Metabolomics
Received: 21 Dec 2024; Accepted: 15 Apr 2025.
Copyright: © 2025 Hanna, Abbas, Yassine, Albush and Bilen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Melhem Bilen, Department of Experimental Pathology and Immunology, Faculty of Medicine, American University of Beirut, Beirut, 1107 2020, Lebanon
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.